newsfilter
← Latest News
Business Wire·

AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results

  • AtriCure, Inc. reported Q4 2025 worldwide revenue of $140.5 million, a 13.1% year-over-year increase
  • Q4 2025 net income was $1.8 million with positive adjusted EBITDA of $19.9 million
  • Full year 2025 worldwide revenue reached $534.5 million, representing a 14.9% year-over-year growth
  • Full year 2025 resulted in a net loss of $11.4 million but achieved positive adjusted EBITDA of $61.8 million
  • 2025 growth was driven by expanding adoption of cryoSPHERE MAX, AtriClip FLEX-Mini, and EnCompass clamp products
  • Q4 2025 U.S. revenue increased 12.6% to $114.3 million while international revenue grew 15.3% to $26.2 million
  • Gross margin for Q4 2025 stood at 75.0%, an increase of 45 basis points from the prior year quarter
  • Management projects 2026 revenue between $600 million to $610 million, reflecting 12% to 14% growth
  • 2026 adjusted EBITDA is forecasted to be between $80 million to $82 million with full-year positive net income
  • AtriCure will host a conference call on February 17, 2026, at 4:30 p.m. Eastern Time to discuss results